MedTrace Logo

Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

NCT02929485 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-11-16

No results posted yet for this study

Summary

In this study, the investigators are looking at how people make decisions about reward-related items, both monetary and food related after taking either the dopamine agonist bromocriptine or the COMT inhibitor tolcapone, in healthy control subjects. Subjects will fill self-report questionnaires and undergo an MRI scan.

Conditions

Interventions

DRUG

Tolcapone

Tolcapone 200mg (single dose) administered at study visit

DRUG

Placebo

Placebo (200mg) administered at study visit

DRUG

Bromocriptine

Drug: Bromocriptine 1.25 mg (single dose) administered at study visit

Sponsors & Collaborators

Principal Investigators

  • Andrew Kayser, MD,PhD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2018-01-31
Completion
2018-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02929485 on ClinicalTrials.gov